← Back to Screener
Galmed Pharmaceuticals Ltd. (GLMD)
Price$0.70
Value ScoreA
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-33.87%
Price vs S&P 500 (4W)13.92%
VGM Score66.42
Market Capitalization$4.59M
All Metrics
Book Value / Share (Quarterly)$2.40
P/TBV (Annual)0.09x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.96
Price vs S&P 500 (YTD)-15.42%
Net Profit Margin (TTM)-424.24%
EPS (TTM)$-2.40
10-Day Avg Trading Volume0.12M
EPS Excl Extra (TTM)$-2.40
EPS (Annual)$-8.09
ROI (Annual)-46.06%
Net Profit Margin (5Y Avg)-5369.04%
Cash / Share (Quarterly)$1.67
ROA (Last FY)-40.65%
EBITD / Share (TTM)$-2.55
ROE (5Y Avg)-80.13%
Operating Margin (TTM)-439.83%
Cash Flow / Share (Annual)$-0.96
P/B Ratio0.29x
P/B Ratio (Quarterly)0.26x
Net Income / Employee (Annual)$-2,506,700
EV / Revenue (TTM)0.26x
Net Interest Coverage (TTM)-93.05x
ROA (TTM)-50.39%
EPS Incl Extra (Annual)$-8.09
Current Ratio (Annual)6.55x
Quick Ratio (Quarterly)6.55x
3-Month Avg Trading Volume2.13M
52-Week Price Return-53.29%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$6.28
P/S Ratio (Annual)2.25x
Asset Turnover (Annual)0.02x
52-Week High$2.34
Operating Margin (5Y Avg)-5585.52%
EPS Excl Extra (Annual)$-8.09
Tangible BV CAGR (5Y)-3.20%
26-Week Price Return-25.95%
Quick Ratio (Annual)6.45x
13-Week Price Return10.48%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)6.55x
Enterprise Value$608,400
Asset Turnover (TTM)0.04x
Book Value / Share Growth (5Y)-40.10%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-479.41%
Cash / Share (Annual)$1.67
3-Month Return Std Dev97.88%
Net Income / Employee (TTM)$-3,436,300
ROE (Last FY)-46.06%
Net Interest Coverage (Annual)-6.64x
EPS Basic Excl Extra (Annual)$-8.09
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.40
ROI (TTM)-57.04%
P/S Ratio (TTM)1.99x
Pretax Margin (5Y Avg)-5365.36%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$7.99
Price vs S&P 500 (52W)-77.65%
Year-to-Date Return-7.26%
5-Day Price Return-4.29%
EPS Normalized (Annual)$-8.09
ROA (5Y Avg)-66.75%
Net Profit Margin (Annual)-483.33%
Month-to-Date Return-7.64%
Cash Flow / Share (TTM)$-6.77
EBITD / Share (Annual)$-7.89
Operating Margin (Annual)-525.49%
ROI (5Y Avg)-80.13%
EPS Basic Excl Extra (TTM)$-2.40
P/TBV (Quarterly)0.12x
P/B Ratio (Annual)0.26x
Pretax Margin (TTM)-420.78%
Book Value / Share (Annual)$2.40
Price vs S&P 500 (13W)2.22%
Beta0.67x
Revenue / Share (TTM)$0.00
ROE (TTM)-57.04%
52-Week Low$0.41
vGradeA
mGradeC
vgmGradeB
Show chart for
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
2.17
2.17
2.17
2.17
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
GLMDGalmed Pharmaceuticals Ltd. | A | — | C | $0.70 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Galmed Pharmaceuticals is a biopharmaceutical company developing Aramchol, a novel therapeutic candidate for liver disease. The company previously focused Aramchol on non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC), as well as other fibro-inflammatory conditions. Galmed is now advancing development of Aramchol for oncological applications, representing a strategic expansion of the program's potential therapeutic uses.